Clinical trial NCT06356883 - References

Glioblastoma Multiforme — Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma

Citation(s)

•   Bradbury MW
  The developing experimental approach to the idea of a blood-brain barrier. Ann N Y Acad Sci. 1986;481:137-41. doi: 10.1111/j.1749-6632.1986.tb27146.x. No abstract available.
•   Bradford R, Koppel H, Pilkington GJ, Thomas DG, Darling JL
  Heterogeneity of chemosensitivity in six clonal cell lines derived from a spontaneous murine astrocytoma and its relationship to genotypic and phenotypic characteristics. J Neurooncol. 1997 Sep;34(3):247-61. doi: 10.1023/a:1005704223040.
•   Drapeau A, Fortin D
  Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous. Curr Cancer Drug Targets. 2015;15(9):752-68. doi: 10.2174/1568009615666150616123548.
•   Fortin D, Morin PA, Belzile F, Mathieu D, Pare FM
  Intra-arterial carboplatin as a salvage strategy in the treatment of recurrent glioblastoma multiforme. J Neurooncol. 2014 Sep;119(2):397-403. doi: 10.1007/s11060-014-1504-4. Epub 2014 Jun 20.
•   Fortin D, Salame JA, Desjardins A, Benko A
  Technical modification in the intracarotid chemotherapy and osmotic blood-brain barrier disruption procedure to prevent the relapse of carboplatin-induced orbital pseudotumor. AJNR Am J Neuroradiol. 2004 May;25(5):830-4.
•   Fortin D
  [The blood-brain barrier should not be underestimated in neuro-oncology]. Rev Neurol (Paris). 2004 May;160(5 Pt 1):523-32. doi: 10.1016/s0035-3787(04)70981-9. French.
•   Fortin D
  Drug Delivery Technology to the CNS in the Treatment of Brain Tumors: The Sherbrooke Experience. Pharmaceutics. 2019 May 27;11(5):248. doi: 10.3390/pharmaceutics11050248.
•   Go RS, Adjei AA
  Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999 Jan;17(1):409-22. doi: 10.1200/JCO.1999.17.1.409.
•   Koukourakis MI, Koukouraki S, Fezoulidis I, Kelekis N, Kyrias G, Archimandritis S, Karkavitsas N
  High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br J Cancer. 2000 Nov;83(10):1281-6. doi: 10.1054/bjoc.2000.1459.
•   Kroll RA, Neuwelt EA
  Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery. 1998 May;42(5):1083-99; discussion 1099-100. doi: 10.1097/00006123-199805000-00082.
•   Leao DJ, Craig PG, Godoy LF, Leite CC, Policeni B
  Response Assessment in Neuro-Oncology Criteria for Gliomas: Practical Approach Using Conventional and Advanced Techniques. AJNR Am J Neuroradiol. 2020 Jan;41(1):10-20. doi: 10.3174/ajnr.A6358. Epub 2019 Dec 19.
•   Newton HB, Figg GM, Slone HW, Bourekas E
  Incidence of infusion plan alterations after angiography in patients undergoing intra-arterial chemotherapy for brain tumors. J Neurooncol. 2006 Jun;78(2):157-60. doi: 10.1007/s11060-005-9080-2. Epub 2006 Apr 14.
•   Newton HB, Slivka MA, Volpi C, Bourekas EC, Christoforidis GA, Baujan MA, Slone W, Chakeres DW
  Intra-arterial carboplatin and intravenous etoposide for the treatment of metastatic brain tumors. J Neurooncol. 2003 Jan;61(1):35-44. doi: 10.1023/a:1021218207015.
•   Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF
  Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010 Apr 20;28(12):2051-7. doi: 10.1200/JCO.2009.26.5520. Epub 2010 Mar 22. Erratum In: J Clin Oncol. 2010 Jul 20;28(21):3543.
•   Quant EC, Wen PY
  Response assessment in neuro-oncology. Curr Oncol Rep. 2011 Feb;13(1):50-6. doi: 10.1007/s11912-010-0143-y.
•   Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, Montrose MH, Beck WT, Erickson LC
  Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther. 2008 Jan;324(1):95-102. doi: 10.1124/jpet.107.127704. Epub 2007 Oct 18.
•   Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group
  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96. doi: 10.1056/NEJMoa043330.
•   Wagner S, Peters O, Fels C, Janssen G, Liebeskind AK, Sauerbrey A, Suttorp M, Hau P, Wolff JE
  Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors. J Neurooncol. 2008 Jan;86(2):175-81. doi: 10.1007/s11060-007-9444-x. Epub 2007 Jul 20.
•   Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H
  Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):481-6. doi: 10.1007/s004320050305.

A Randomized Phase II Study on Intraarterial Carboplatin Combined With Caelyx Compared to Intraarterial Carboplatin Combined With Etoposide Phosphate for Progressing Glioblastoma at First or Second Relapse

Details for clinical trial NCT06356883